New strategies for immunosuppression: interfering with cytokines by targeting the Jak/Stat pathway (original) (raw)
Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection
Paul Changelian
Journal of Medicinal Chemistry, 2010
View PDFchevron_right
Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor
Matthew Brown, Ming-sing Si, Ricardo Paniagua
Science, 2003
View PDFchevron_right
Clinical perspectives of Janus Kinase Inhibitors: A review
Sadanand Mallurwar
Asian Journal of Pharmacy and Pharmacology
View PDFchevron_right
Janus kinase inhibitors in autoimmune diseases
Yoshiya Tanaka
Annals of the Rheumatic Diseases, 2013
View PDFchevron_right
Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent
Antonis Fanouriakis
Cells
View PDFchevron_right
The Novel JAK-3 Inhibitor CP-690550 Is a Potent Immunosuppressive Agent in Various Murine Models
Paul Changelian
American Journal of Transplantation, 2004
View PDFchevron_right
Suppression of early T-cell???receptor-triggered cellular activation by the Janus kinase 3 inhibitor WHI-P-154
Ornella Parolini
Transplantation, 2003
View PDFchevron_right
VX-509 (Decernotinib) Is a Potent and Selective Janus Kinase 3 Inhibitor That Attenuates Inflammation in Animal Models of Autoimmune Disease
Sudipta Mahajan
The Journal of pharmacology and experimental therapeutics, 2015
View PDFchevron_right
Suppression of Autoimmune Arthritis by Small Molecule Inhibitors of the JAK/STAT Pathway
C. Malemud
Pharmaceuticals, 2010
View PDFchevron_right
Therapeutic Targeting of the JAK/STAT Pathway
Saara Aittomaki
Basic & Clinical Pharmacology & Toxicology, 2014
View PDFchevron_right
Suppression of Early T-Cell Receptor-Triggered Cellular Activation by the Janus Kinase 3 Inhibitor WHI-P-1541
G. Zlabinger
Transplantation, 2003
View PDFchevron_right
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement
Joel Kremer
Annals of the Rheumatic Diseases, 2020
View PDFchevron_right
Therapeutic targeting of Janus kinases
John O'Shea
Immunological Reviews, 2008
View PDFchevron_right
Defective JAK-STAT Pathway Signaling Contributes to Autoimmune Diseases
Charles Malemud
Current Pharmacology Reports, 2018
View PDFchevron_right
Janus kinases in immune cell signaling
John O'Shea
Immunological Reviews, 2009
View PDFchevron_right
JAK/STAT Signal Transduction: Promising Attractive Targets for Immune, Inflammatory and Hematopoietic Diseases
sami shaikh
Current Drug Targets, 2018
View PDFchevron_right
Janus kinases to jakinibs: from basic insights to clinical practice
Olli Silvennoinen
Rheumatology, 2019
View PDFchevron_right
Repurposed JAK1/JAK2 Inhibitor Reverses Established Autoimmune Insulitis in NOD Mice
Misty Jenkins
Diabetes, 2017
View PDFchevron_right
Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases
Juuli Raivola
BioDrugs
View PDFchevron_right
Suppression of Pro-Inflammatory Cytokines via Targeting of STAT-Responsive Genes
Charles Malemud
Drug Discovery, 2013
View PDFchevron_right
Janus kinase 3 inhibition with CP‐690,550 prevents allograft vasculopathy
Paul Changelian
Transplant …, 2006
View PDFchevron_right
Cytokine receptor signal transduction through Jak tyrosine kinases and Stat transcription factors
Olli Silvennoinen
APMIS, 1997
View PDFchevron_right
Suppressors of cytokine signaling in health and disease
Ralph Rabkin
Pediatric Nephrology, 2005
View PDFchevron_right
Jak Inhibitors for Treatment of Autoimmune Diseases: Lessons from Systemic Sclerosis and Systemic Lupus Erythematosus
Przemyslaw Kotyla
Pharmaceuticals
View PDFchevron_right
JAK1/STAT3 activation directly inhibits IL-12 production in dendritic cells by preventing CDK9/P-TEFb recruitment to the p35 promoter
Christine Falk
Biochemical pharmacology, 2015
View PDFchevron_right
[Inhibition of the Janus kinase-signal transducer and activator of transcription is a new treatment modality of rheumatoid arthritis]
Bent Deleuran
PubMed, 2017
View PDFchevron_right
JAK-STAT Pathway Inhibition and their Implications in COVID-19 Therapy
Roshitha Shaji
Postgraduate Medicine, 2020
View PDFchevron_right
Small Molecule Inhibitors of Interferon‐Induced JAK‐STAT Signalling
ahmed EL MARJOU
Angewandte Chemie
View PDFchevron_right
Discovery of VX-509 (Decernotinib): A Potent and Selective Janus kinase (JAK) 3 Inhibitor for the Treatment of Autoimmune Diseases
Christopher Brummel
Journal of medicinal chemistry, 2015
View PDFchevron_right
Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin
Rebeca Cohen
Blood, 2002
View PDFchevron_right
Biological and clinical significance of the JAK-STAT pathway; lessons from knockout mice
Peter Igaz
Inflammation Research, 2001
View PDFchevron_right
The regulation of JAKs in cytokine signaling and its breakdown in disease
Juuli Raivola
Cytokine, 2018
View PDFchevron_right
The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells
farhad seif
Cell communication and signaling : CCS, 2017
View PDFchevron_right
JAK/STAT Pathways in Cytokine Signaling and Myeloproliferative Disorders: Approaches for Targeted Therapies
Lewis Silverman
Genes & Cancer, 2010
View PDFchevron_right
A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis
Cynthia Serdikoff
Arthritis Research & Therapy, 2011
View PDFchevron_right